Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy

por David Bobrowski, Reha Kumar, Peter E. Wu, Lauren Lapointe‐Shaw
Publicado 2021

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors

por Santos Cavaiola T, Pettus J
Publicado 2018

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors

por Fan Yang, Ran Meng, Da-Long Zhu
Publicado 2020

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence

por Bonora BM, Avogaro A, Fadini GP
Publicado 2020

Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Ja...

por Ito H, Matsumoto S, Izutsu T, Kusano E, Nishio S, Antoku S, Yamasaki T, Mori T, Togane M, Ando S, Tsugami E
Publicado 2019

Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance...

por K. Tobe, H. Maegawa, I. Nakamura, S. Uno
Publicado 2021

The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers

por Hirai K, Morino J, Minato S, Kaneko S, Yanai K, Mutsuyoshi Y, Ishii H, Matsuyama M, Kitano T, Shindo M, Aomatsu A, Miyazawa H, Ito K, Ueda Y, Ookawara S, Morishita Y
Publicado 2020

Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors

por A. M. Mkrtumyan, T. N. Markova, N. K. Mishchenko
Publicado 2021